Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash & Equivalents (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Cash & Equivalents data on record, last reported at $36.2 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 10.43% year-over-year to $36.2 million; the TTM value through Sep 2025 reached $36.2 million, down 10.43%, while the annual FY2024 figure was $29.9 million, 54.23% down from the prior year.
  • Cash & Equivalents reached $36.2 million in Q3 2025 per BTAI's latest filing, up from $17.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $233.5 million in Q2 2022 and bottomed at $17.4 million in Q2 2025.
  • Average Cash & Equivalents over 4 years is $106.2 million, with a median of $74.1 million recorded in 2024.
  • The widest YoY moves for Cash & Equivalents: up 10.43% in 2025, down 69.02% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $193.7 million in 2022, then crashed by 66.33% to $65.2 million in 2023, then crashed by 54.23% to $29.9 million in 2024, then rose by 21.18% to $36.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $36.2 million in Q3 2025, $17.4 million in Q2 2025, and $31.0 million in Q1 2025.